Zentalis Pharmaceuticals, Inc. (ZNTL)

Market Cap	889.84M
Revenue (ttm)	n/a
Net Income (ttm)	-292.19M
Shares Out	70.96M
EPS (ttm)	-4.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	678,124
Open	12.73
Previous Close	12.71
Day's Range	12.50 - 12.94
52-Week Range	9.56 - 31.46
Beta	1.73
Analysts	Strong Buy
Price Target	43.57 (+247.45%)
Earnings Date	May 8, 2024

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 3, 2020
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: ZNTL

Analyst Forecast

According to 7 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is $43.57, which is an increase of 247.45% from the latest price.

Price Target

$43.57

(247.45% upside)

Analyst Consensus: Strong Buy